GlassScriptPhysician profile
Vipin Ohri
NPI 1770535064
$14,156.81
in general payments reported to CMS, 2019-2025
28 companies · $964 in 2025
The $964 reported for 2025 was more than what 83% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $2,014 · 2021: $3,147 · 2022: $2,141 · 2023: $2,034 · 2024: $2,003 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,000.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,682.87 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Amgen INC. | $1,805.73 | 2019-2025 | Otezla, Repatha, Repatha |
| Biotronik INC. | $1,570.76 | 2019-2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| Glaxosmithkline, LLC. | $1,364.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,116.91 | 2019-2022 | |
| Pfizer INC. | $1,058.28 | 2019-2023 | |
| Lilly USA, LLC | $931.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $788.35 | 2019-2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $732.03 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $313.86 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Teva Pharmaceuticals USA, INC. | $229.14 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.05 | 2023-2024 | |
| Edwards Lifesciences Corporation | $201.95 | 2021-2023 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $168.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $138.06 | 2020-2021 | |
| Endologix LLC | $130.20 | 2021 | |
| Amarin Pharma, INC. | $94.32 | 2019-2021 | |
| Gilead Sciences, INC. | $94.06 | 2021-2023 | Epclusa |
| Merck Sharp & Dohme LLC | $70.54 | 2019-2021 | |
| Sk Life Science, INC. | $36.69 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $31.69 | 2022-2023 | Eliquis |
| Astellas Pharma US INC | $28.78 | 2019 | |
| Cvrx, INC. | $18.54 | 2024 | Barostim Neo System |
| Phathom Pharmaceuticals, INC. | $17.85 | 2024 | Voquezna |
| Medtronic, INC. | $17.46 | 2023 | Mycarelink |
| Regeneron Healthcare Solutions, INC. | $12.86 | 2019 | |
| Abbvie INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipin Ohri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.